Arrowhead said its RNA interference drug Redemplo showed a safety edge over Ionis Pharmaceuticals’ Wainua in the late-stage setting of ATTR-CM, intensifying focus on tolerability as efficacy comparisons continue. The companies’ programs sit in a dense pipeline area where silencers compete against stabilizers, and analyst debate has centered on whether adding gene-silencing therapy provides incremental benefit for patients already receiving standard stabilizer drugs. The next inflection points are expected to come from final readouts and positioning in treatment sequences, with Redemplo’s safety framing aimed at strengthening its clinical and commercial narrative.